These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 16598777

  • 21. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 22. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H.
    Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
    [Abstract] [Full Text] [Related]

  • 23. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 24. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T, Argudo A, Peña-Cala MC.
    Transplant Proc; 2011 Oct; 43(6):2216-9. PubMed ID: 21839237
    [Abstract] [Full Text] [Related]

  • 25. Everolimus de novo in liver transplantation.
    Calmus Y, Durrbach A.
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S247-52. PubMed ID: 20004330
    [Abstract] [Full Text] [Related]

  • 26. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.
    Montagnino G, Sandrini S, Casciani C, Schena FP, Carmellini M, Civati G, Rigotti P, Cossu M, Altieri P, Salvadori M, Federico S, Stefoni S, Cambi V, Albertazzi A, Buoncristiani U, Berloco P, Segoloni G, Boschiero L, Sparacino V, Donati D, Turello E, Dal Canton A, Ponticelli C.
    Transplant Proc; 2005 Mar; 37(2):788-90. PubMed ID: 15848532
    [Abstract] [Full Text] [Related]

  • 27. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 28. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
    Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C.
    Transplantation; 2002 Mar 27; 73(6):920-5. PubMed ID: 11923693
    [Abstract] [Full Text] [Related]

  • 29. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
    Budde K, Lehne G, Winkler M, Renders L, Lison A, Fritsche L, Soulillou JP, Fauchald P, Neumayer HH, Dantal J, RADW 102 Renal Transplant Study Group.
    J Clin Pharmacol; 2005 Jul 27; 45(7):781-91. PubMed ID: 15951468
    [Abstract] [Full Text] [Related]

  • 30. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
    Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G.
    Liver Transpl; 2001 May 27; 7(5):401-8. PubMed ID: 11349259
    [Abstract] [Full Text] [Related]

  • 31. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.
    Tedesco-Silva H, Lorber MI, Foster CE, Sollinger HW, Mendez R, Carvalho DB, Shapiro R, Rajagopalan PR, Mayer H, Slade J, Kahan BD, FTY720A2202 clinical study group.
    Clin Transplant; 2009 May 27; 23(5):589-99. PubMed ID: 19719728
    [Abstract] [Full Text] [Related]

  • 32. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [Abstract] [Full Text] [Related]

  • 33. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.
    Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M, CRADUS09 Study Group.
    Transplantation; 2008 Mar 27; 85(6):821-6. PubMed ID: 18360262
    [Abstract] [Full Text] [Related]

  • 34. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
    Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM.
    Liver Transpl; 2009 May 27; 15(5):504-8. PubMed ID: 19399742
    [Abstract] [Full Text] [Related]

  • 35. Severe atopic dermatitis treated with everolimus.
    Van Velsen SG, Haeck IM, Bruijnzeel-Koomen CA.
    J Dermatolog Treat; 2009 May 27; 20(6):365-7. PubMed ID: 19954394
    [Abstract] [Full Text] [Related]

  • 36. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
    Hummel M.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S196-200; discussion S210-1. PubMed ID: 15774322
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
    Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E, RAD A2420 Study Group.
    Transpl Int; 2010 Nov 27; 23(11):1084-93. PubMed ID: 20500493
    [Abstract] [Full Text] [Related]

  • 38. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May 27; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 39. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 40. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep 27; 38(7):2032-4. PubMed ID: 16979990
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.